TipRanks
Inventiva (DE:6IVA)
FRANKFURT:6IVA
Germany Market
6IVA
Inventiva
RESEARCH TOOLSreports

Inventiva (6IVA) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

6IVA Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Inventiva
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6IVA Stock 12 Month Forecast

Average Price Target

€13.81
▲(269.14% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Inventiva in the last 3 months. The average price target is €13.81 with a high forecast of €23.16 and a low forecast of €8.91. The average price target represents a 269.14% change from the last price of €3.74.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","24":"€24","6.75":"€6.75","12.5":"€12.5","18.25":"€18.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23.15818908,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€23.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":13.805843489999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€13.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8.9069958,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€8.91</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,6.75,12.5,18.25,24],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,4.439860698461539,5.999721396923077,7.559582095384616,9.119442793846154,10.679303492307692,12.23916419076923,13.799024889230768,15.358885587692306,16.918746286153844,18.478606984615382,20.03846768307692,21.59832838153846,{"y":23.15818908,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,3.720449499230769,4.560898998461538,5.401348497692307,6.241797996923076,7.082247496153845,7.922696995384614,8.763146494615384,9.603595993846152,10.44404549307692,11.284494992307689,12.12494449153846,12.965393990769229,{"y":13.805843489999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.88,3.3436150615384617,3.807230123076923,4.270845184615385,4.734460246153846,5.198075307692308,5.66169036923077,6.125305430769231,6.588920492307693,7.0525355538461545,7.516150615384616,7.979765676923077,8.443380738461538,{"y":8.9069958,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.96,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.639,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.1,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.98,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.14,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.82,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.8,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€23.16Average Price Target€13.81Lowest Price Target€8.91
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on DE:6IVA
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
10/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on DE:6IVA
Michael Yee
UBS
UBS
€10.69
Buy
185.79%
Upside
Reiterated
09/30/26
Analysts Are Bullish on These Healthcare Stocks: Pharming Group (PHAR), Inventiva (IVA)
Leerink Partners Analyst forecast on DE:6IVA
Thomas Smith
Leerink Partners
Leerink Partners
€10.69
Buy
185.79%
Upside
Reiterated
09/29/26
Inventiva (IVA) Receives a Rating Update from a Top Analyst
Canaccord Genuity Analyst forecast on DE:6IVA
Edward Nash
Canaccord Genuity
Canaccord Genuity
€17.81→€18.7
Buy
400.13%
Upside
Reiterated
09/29/26
Inventiva price target raised to $21 from $20 at CanaccordInventiva price target raised to $21 from $20 at Canaccord
TD Cowen Analyst forecast on DE:6IVA
Ritu Baral
TD Cowen
TD Cowen
€8.91
Buy
138.15%
Upside
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)
Guggenheim Analyst forecast on DE:6IVA
Seamus Fernandez
Guggenheim
Guggenheim
€12.47
Buy
233.42%
Upside
Reiterated
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Adagene (NASDAQ: ADAG) and Inventiva (NASDAQ: IVA)
LifeSci Capital Analyst forecast on DE:6IVA
Rami Katkhuda
LifeSci Capital
LifeSci Capital
€12.47
Buy
233.42%
Upside
Reiterated
09/28/26
Analyst Initiates Buy on Inventiva, Citing De-Risked Lanifibranor Profile and Strong Setup Ahead of NATiV3 Topline Data
Stifel Nicolaus Analyst forecast on DE:6IVA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€13.36
Buy
257.23%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Celldex (NASDAQ: CLDX) and Inventiva (NASDAQ: IVA)
Piper Sandler Analyst forecast on DE:6IVA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€23.16
Buy
519.20%
Upside
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA) and Amneal Pharmaceuticals (NASDAQ: AMRX)
Cantor Fitzgerald Analyst forecast on DE:6IVA
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
07/17/26
Inventiva initiated with an Overweight at Cantor FitzgeraldInventiva initiated with an Overweight at Cantor Fitzgerald
Barclays Analyst forecast on DE:6IVA
Eliana Merle
Barclays
Barclays
€16.03
Buy
328.68%
Upside
Reiterated
06/04/26
Inventiva (IVA) Receives a Buy from Barclays
H.C. Wainwright Analyst forecast on DE:6IVA
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
€21.38
Buy
471.57%
Upside
Reiterated
01/28/26
Analysts' Top Healthcare Picks: Aclaris Therapeutics (ACRS), Inventiva (IVA)
Wolfe Research Analyst forecast on DE:6IVA
Andy Chen
Wolfe Research
Wolfe Research
€11.58
Buy
209.60%
Upside
Initiated
11/05/25
Inventiva initiated with an Outperform at Wolfe ResearchInventiva initiated with an Outperform at Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Truist Financial Analyst forecast on DE:6IVA
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
10/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
UBS Analyst forecast on DE:6IVA
Michael Yee
UBS
UBS
€10.69
Buy
185.79%
Upside
Reiterated
09/30/26
Analysts Are Bullish on These Healthcare Stocks: Pharming Group (PHAR), Inventiva (IVA)
Leerink Partners Analyst forecast on DE:6IVA
Thomas Smith
Leerink Partners
Leerink Partners
€10.69
Buy
185.79%
Upside
Reiterated
09/29/26
Inventiva (IVA) Receives a Rating Update from a Top Analyst
Canaccord Genuity Analyst forecast on DE:6IVA
Edward Nash
Canaccord Genuity
Canaccord Genuity
€17.81→€18.7
Buy
400.13%
Upside
Reiterated
09/29/26
Inventiva price target raised to $21 from $20 at CanaccordInventiva price target raised to $21 from $20 at Canaccord
TD Cowen Analyst forecast on DE:6IVA
Ritu Baral
TD Cowen
TD Cowen
€8.91
Buy
138.15%
Upside
Reiterated
09/28/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA) and Moderna (NASDAQ: MRNA)
Guggenheim Analyst forecast on DE:6IVA
Seamus Fernandez
Guggenheim
Guggenheim
€12.47
Buy
233.42%
Upside
Reiterated
09/28/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Adagene (NASDAQ: ADAG) and Inventiva (NASDAQ: IVA)
LifeSci Capital Analyst forecast on DE:6IVA
Rami Katkhuda
LifeSci Capital
LifeSci Capital
€12.47
Buy
233.42%
Upside
Reiterated
09/28/26
Analyst Initiates Buy on Inventiva, Citing De-Risked Lanifibranor Profile and Strong Setup Ahead of NATiV3 Topline Data
Stifel Nicolaus Analyst forecast on DE:6IVA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
€13.36
Buy
257.23%
Upside
Reiterated
09/23/26
Analysts Offer Insights on Healthcare Companies: Merck & Company (NYSE: MRK), Celldex (NASDAQ: CLDX) and Inventiva (NASDAQ: IVA)
Piper Sandler Analyst forecast on DE:6IVA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
€23.16
Buy
519.20%
Upside
Reiterated
09/16/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA) and Amneal Pharmaceuticals (NASDAQ: AMRX)
Cantor Fitzgerald Analyst forecast on DE:6IVA
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Initiated
07/17/26
Inventiva initiated with an Overweight at Cantor FitzgeraldInventiva initiated with an Overweight at Cantor Fitzgerald
Barclays Analyst forecast on DE:6IVA
Eliana Merle
Barclays
Barclays
€16.03
Buy
328.68%
Upside
Reiterated
06/04/26
Inventiva (IVA) Receives a Buy from Barclays
H.C. Wainwright Analyst forecast on DE:6IVA
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
€21.38
Buy
471.57%
Upside
Reiterated
01/28/26
Analysts' Top Healthcare Picks: Aclaris Therapeutics (ACRS), Inventiva (IVA)
Wolfe Research Analyst forecast on DE:6IVA
Andy Chen
Wolfe Research
Wolfe Research
€11.58
Buy
209.60%
Upside
Initiated
11/05/25
Inventiva initiated with an Outperform at Wolfe ResearchInventiva initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
IMUXImmunic
REPLReplimune Group
OVIDOvid Therapeutics
CELCCelcuity
ARDXArdelyx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inventiva

3 Months
Ritu BaralTD Cowen
Success Rate
5/9 ratings generated profit
56%
Average Return
+10.07%
Copying Ritu Baral's trades and holding each position for 3 Months would result in 55.56% of your transactions generating a profit, with an average return of +10.07% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
5/9 ratings generated profit
56%
Average Return
+26.86%
Copying Ritu Baral's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +26.86% per trade.
2 Years
Annabel SamimyStifel Nicolaus
Success Rate
12/18 ratings generated profit
67%
Average Return
+21.72%
Copying Annabel Samimy's trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +21.72% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6IVA Analyst Recommendation Trends

Rating
Jun 26
Jul 26
Aug 26
Sep 26
Oct 26
Strong Buy
10
8
7
13
10
Buy
2
3
2
3
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
12
11
9
16
12
In the current month, 6IVA has received 12 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6IVA average Analyst price target in the past 3 months is 13.81.
Each month's total comprises the sum of three months' worth of ratings.

6IVA Financial Forecast

6IVA Earnings Forecast

Next quarter’s earnings estimate for 6IVA is -€0.30 with a range of -€0.39 to -€0.21. The previous quarter’s EPS was -€0.18. 6IVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6IVA has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6IVA is -€0.30 with a range of -€0.39 to -€0.21. The previous quarter’s EPS was -€0.18. 6IVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 6IVA has Performed in-line its overall industry.

6IVA Sales Forecast

Next quarter’s sales forecast for 6IVA is €4.20M with a range of €0.00 to €10.09M. The previous quarter’s sales results were €20.72K. 6IVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6IVA has Performed in-line its overall industry.
Next quarter’s sales forecast for 6IVA is €4.20M with a range of €0.00 to €10.09M. The previous quarter’s sales results were €20.72K. 6IVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 6IVA has Performed in-line its overall industry.

6IVA Stock Forecast FAQ

What is DE:6IVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Inventiva’s 12-month average price target is 13.81.
    What is DE:6IVA’s upside potential, based on the analysts’ average price target?
    Inventiva has 269.14% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Inventiva a Buy, Sell or Hold?
          Inventiva has a consensus rating of Strong Buy, which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Inventiva’s share price target?
            The average share price target for Inventiva is 13.81. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €23.16 ,and the lowest forecast is €8.91. The average share price target represents 269.14% Increase from the current price of €3.74.
              What do analysts say about Inventiva?
              Inventiva’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of Inventiva?
                To buy shares of DE:6IVA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.